


**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : <b>A61K 47/48, 48/00, C12N 15/19, 15/62, 15/29, 15/31, C07K 14/52, 19/00, 14/415</b>		<b>A3</b>	(11) International Publication Number: <b>WO 00/04926</b>
			(43) International Publication Date: 3 February 2000 (03.02.00)
(21) International Application Number: <b>PCT/CA99/00659</b>		(74) Agents: MORROW, Joy, D. et al.; Smart & Biggar, 900-55 Metcalfe Street, Station D., P.O. Box 2999, Ottawa, Ontario K1P 5Y6 (CA).	
(22) International Filing Date: 21 July 1999 (21.07.99)			
(30) Priority Data: 09/120,523 22 July 1998 (22.07.98) <b>US</b>		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application <b>US</b> 09/120,523 (CIP) Filed on 22 July 1998 (22.07.98)			
(71) Applicant (for all designated States except US): OSPREY PHARMACEUTICALS LIMITED [CA/CA]; 3400 Petro-Canada Centre, 150-6th Avenue SW, Calgary, Alberta T2P 3Y7 (CA).			
(72) Inventors; and (75) Inventors/Applicants (for US only): MCDONALD, John, R. [GB/CA]; 60 Governor Drive SW, Calgary, Alberta T3E 4Y9 (CA). COGGINS, Philip, J. [CA/CA]; 4211, 5A Street SW, Calgary, Alberta T2S 2G8 (CA).		Published With international search report.	
		(88) Date of publication of the international search report: 2 November 2000 (02.11.00)	

**(54) Title: METHODS AND COMPOSITIONS FOR TREATING SECONDARY TISSUE DAMAGE AND OTHER INFLAMMATORY CONDITIONS AND DISORDERS****(57) Abstract**

Conjugates containing as a ligand a chemokine receptor targeting agents, such as chemokines, and a targeted agent, such as a toxin are provided. These conjugates are used to treat inflammatory responses associated with activation, proliferation and migration of immune effector cells, including leukocyte cell types, neutrophils, macrophages, and eosinophils. The conjugates provided herein are used to lessen or inhibit these processes to prevent or at least lessen the resulting secondary effects. In particular, the conjugates are used to target toxins to receptors on secondary tissue damage-promoting cells. The ligand moiety can be selected to deliver the cell toxin to such secondary tissue damage-promoting cells as mononuclear phagocytes, leukocytes, natural killer cells, dendritic cells, and T and B lymphocytes, thereby suppressing the proliferation, migration, or physiological activity of such cells. Among preferred conjugates are fusion proteins having a chemokine, or a biologically active fragment thereof, as the ligand moiety linked to a cell toxin via a peptide linker of from 2 to about 60 amino acid residues.



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

# INTERNATIONAL SEARCH REPORT

International Application No  
PC1/CA 99/00659

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K47/48 A61K48/00 C12N15/19 C12N15/62 C12N15/29  
C12N15/31 C07K14/52 C07K19/00 C07K14/415

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	P ROBY ET AL: "Melanoma-specific cytotoxicity of a human MGSA/GROalpha C-terminal peptide conjugated to daunorubicin" ONCOLOGY REPORTS, vol. 3, 1996, pages 175-179, XP000881561 abstract "Cytotoxicity..Etc" on pages 177 to 178 discussion ---	1-43,65, 73-75
X	WO 95 12414 A (REPLIGEN CORP) 11 May 1995 (1995-05-11) example 26 claims 16-22 page 9, line 31 -page 10, line 9 --- -/--	1-47,65, 73-75,79



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

### \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"G" document member of the same patent family

Date of the actual completion of the international search

30 June 2000

Date of mailing of the international search report

14.08.00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Pilling, S

# INTERNATIONAL SEARCH REPORT

International Application No  
PCI/CA 99/00659

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 94 07535 A (LYLE LEON R ;UNIV MICHIGAN (US); KUNKEL STEVEN L (US); MALLINCKRODT) 14 April 1994 (1994-04-14) examples 1-8 ---	1-43,65, 73-75
X	D I SILBERT: "Glycosaminoglycans of bovine aorta endothelial cells: Identification and localization by use of a platelet factor 4-fluorescein probe" JOURNAL OF HISTOCHEMISTRY AND CYTOCHEMISTRY, vol. 38, no. 4, 1990, pages 589-593, XP000881557 abstract ---	1-43,65, 73-75
X	WO 94 07542 A (MALLINCKRODT MEDICAL INC ;UNIV MICHIGAN (US)) 14 April 1994 (1994-04-14) examples 1-8 ---	1-43,65, 73-75
X	E RAY ET AL: "Receptor mediated endocytosis of IL-8: a fluorescent microscopic evidence and implication of the process in ligand induced biological response in human neutrophils" CYTOKINE, vol. 9, no. 8, August 1997 (1997-08), pages 587-596, XP000881538 1997 abstract ---	1-43,65, 73-75
A	WO 93 23062 A (IMMUNOMEDICS INC) 25 November 1993 (1993-11-25) the whole document ---	1-79
A	WO 91 18012 A (BIOSPAN CORP) 28 November 1991 (1991-11-28) the whole document ---	1-79
X	WO 90 12597 A (SALK INST FOR BIOLOGICAL STUDIES) 1 November 1990 (1990-11-01) page 3, line 3 - line 22 ---	50-53,58
X	WO 93 25228 A (WHITTIER INST FOR DIABETES AND ;LAPPI DOUGLAS A (US); BAIRD J ANDR) 23 December 1993 (1993-12-23) page 4, line 6 - line 29 page 18, line 9 - line 15 ---	50-64, 67-71, 76-78
X	US 5 326 559 A (MILLER D DOUGLAS) 5 July 1994 (1994-07-05)  column 4, line 37 - line 41 column 8, line 3 - line 17 column 11, line 67 - line 68 ---	50-64, 67-71, 76-78
	---	

-/--

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/CA 99/00659

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	RALPH, P.: "Clinical and preclinical studies presented by the keystone symposium on arthritis" LYMPHOKINE AND CYTOKINE RESEARCH, vol. 12, no. 4, August 1993 (1993-08), pages 261-263, XP000891639 abstract page 262, column 1, line 29 - line 47 ---	50-64, 67-71, 76-78
X	STROM, TERRY B. ET AL: "Interleukin-2 receptor-directed therapies: Antibody- or cytokine-based targeting molecules" ANNU. REV. MED. (1993), 44, 343-53, XP000915772 page 347 -page 351 ---	50-64, 67-71, 76-78
X	NAGPAL, SUNIL ET AL: "New dermatological agents for the treatment of psoriasis" ANNU. REP. MED. CHEM. (1997), 32, 201-210, XP000915751 "Introduction" on page 201 and the "New targets" on page 207 to 208 with reference to "fusion proteins" ---	50-64, 67-71, 76-78
X	ROBERGE, FRANCOIS G. ET AL: "Selective immunosuppression of activated T cells with the chimeric toxin IL - 2 -PE40. Inhibition of experimental autoimmune uveoretinitis" J. IMMUNOL. (1989), 143(11), 3498-502, XP002028689 abstract ---	50-64, 67-71, 76-78
X	DATABASE CHEMABS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US SHEMYAKIN, I. G. ET AL: "Construction and expression in Escherichia coli cells of the fusion protein diphtheria toxin -human interleukin 2" retrieved from STN Database accession no. 119:40509 XP002141203 abstract & MOL. BIOL. (MOSCOW) (1992), 26(5), 1088-98, ---	50-54
X	HUSAIN, SYED R. ET AL: "Complete regression of established human glioblastoma tumor xenograft by interleukin -4 toxin therapy" CANCER RES. (1998), 58(16), 3649-3653, XP000910254 abstract ---	50-53, 64
	--- -/--	

# INTERNATIONAL SEARCH REPORT

International Application No

PL1/CA 99/00659

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MENEGHETTI, CAROLE M. ET AL: "Initial clinical experiences with an interleukin -2 fusion toxin (DAB486- IL - 2 )" TARGETED DIAGN. THER. (1992), 7(GENET. ENG. TOXINS), 395-401, XP000915730 "III the chimeric fusion protein..Etc" on pages 396 to 399 ---	50-53,64
X	US 5 084 556 A (BROWN EUGENE L) 28 January 1992 (1992-01-28) column 5, line 31 -column 5, line 42 ---	50-53,64
X	US 5 152 980 A (STROM TERRY B ET AL) 6 October 1992 (1992-10-06) column 1, line 41 - line 52 -----	50-64, 67-71, 76-78

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/CA 99/00659

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims: it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: Claims 1 to 49, 65, 66,  
72 to 75 and 79 (Claims 52 to 64 and 68 to 71,  
76 to 78 in part)

Conjugates per se comprising (a) a targeted agent and (b) a CHEMOKINE receptor targeting agent which when applied to a receptor bearing cell results in internalization of (a) the targeted agent; associated nucleic acid/cells/pharmaceutical compositions; methods and uses involving said conjugates

2. Claims: Claims 50, 51, 67 (Claims 52 to 64, 68 to 71,  
76 to 78 in part)

Treatment of INFLAMMATORY DISORDERS using a conjugate comprising a NON-CHEMOKINE CYTOKINE



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 99/00659

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9512414 A	11-05-1995	AU 1171795 A	23-05-1995
WO 9407535 A	14-04-1994	US 5346686 A	13-09-1994
		AU 686119 B	05-02-1998
		AU 5353194 A	26-04-1994
		CA 2146239 A	14-04-1994
		EP 0670736 A	13-09-1995
		JP 8511765 T	10-12-1996
		US 5605671 A	25-02-1997
WO 9407542 A	14-04-1994	US 5413778 A	09-05-1995
		AT 150977 T	15-04-1997
		AU 674039 B	05-12-1996
		AU 5403294 A	26-04-1994
		CA 2145983 A	14-04-1994
		DE 69309479 D	07-05-1997
		EP 0662843 A	19-07-1995
		JP 8502075 T	05-03-1996
		US 5605671 A	25-02-1997
WO 9323062 A	25-11-1993	US 5541297 A	30-07-1996
		CA 2118032 A,C	25-11-1993
		EP 0651646 A	10-05-1995
		JP 2942356 B	30-08-1999
		JP 8500084 T	09-01-1996
		US 5601825 A	11-02-1997
WO 9118012 A	28-11-1991	US 5169934 A	08-12-1992
		CA 2059649 A	15-11-1991
		EP 0482185 A	29-04-1992
		JP 5502886 T	20-05-1993
		US 5334391 A	02-08-1994
WO 9012597 A	01-11-1990	US 5191067 A	02-03-1993
		CA 2053275 A,C	28-10-1990
		DE 69010330 D	04-08-1994
		DE 69010330 T	20-10-1994
		EP 0470183 A	12-02-1992
		JP 2891306 B	17-05-1999
		JP 4507093 T	10-12-1992
		US 5576288 A	19-11-1996
		US 5679637 A	21-10-1997
WO 9325228 A	23-12-1993	AU 4532593 A	04-01-1994
US 5326559 A	05-07-1994	WO 9220701 A	26-11-1992
US 5084556 A	28-01-1992	AT 95062 T	15-10-1993
		AU 2728588 A	23-05-1989
		DE 3884621 D	04-11-1993
		EP 0382781 A	22-08-1990
		JP 2518911 B	31-07-1996
		JP 3500879 T	28-02-1991
		WO 8903687 A	05-05-1989
US 5152980 A	06-10-1992	AT 109004 T	15-08-1994
		DE 68917138 D	01-09-1994
		DE 68917138 T	23-02-1995

## Information on patent family members

PL 1/CA 99/00659

Form PCT/ISA/210 (patent family annex) (July 1992)